| [1] |
中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3):235-275.
|
| [2] |
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159):1789-1858.
|
| [3] |
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726.
|
| [4] |
黎俊聪, 黄莹, 杨婵娟, 等. 钠-葡萄糖共转运体2抑制剂治疗心力衰竭的研究进展[J/OL]. 中华心脏与心律电子杂志, 2023, 11(1): 45-49.
|
| [5] |
Kang Y, Liu R, Wu JX, et al. Structural insights into the mechanism of human soluble guanylate cyclase[J]. Nature, 2019, 574(7777):206-210.
|
| [6] |
Adler J, Kuret A, Längst N, et al. Targets of cGMP/cGKI in cardiac myocytes[J]. J Cardiovasc Pharmacol, 2020, 75(6):494-507.
|
| [7] |
Sandner P, Stasch JP. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence[J]. Respir Med, 2017, 122 Suppl 1:S1-S9.
|
| [8] |
Hofmann F. The cGMP system: components and function[J]. Biol Chem, 2020, 401(4):447-469.
|
| [9] |
Münzel T, Gori T, Bruno RM, et al. Is oxidative stress a therapeutic target in cardiovascular disease?[J]. Eur Heart J, 2010, 31(22):2741-2748.
|
| [10] |
Kansakar S, Guragain A, Verma D, et al. Soluble guanylate cyclase stimulators in heart failure[J]. Cureus, 2021, 13(9):e17781.
|
| [11] |
Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure[J]. Heart Fail Rev, 2013, 18(2):123-134.
|
| [12] |
Ben Driss A, Devaux C, Henrion D, et al. Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure[J]. Circulation, 2000, 101(23):2764-2770.
|
| [13] |
Agnoletti L, Curello S, Bachetti T, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha[J]. Circulation, 1999, 100(19):1983-1991.
|
| [14] |
Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis[J]. J Card Fail, 1996, 2(3):243-249.
|
| [15] |
Watanabe H. Treatment selection in pulmonary arterial hypertension: phosphodiesterase type 5 inhibitors versus soluble guanylate cyclase stimulator[J]. Eur Cardiol, 2018, 13(1):35-37.
|
| [16] |
Sandner P, Follmann M, Becker-Pelster E, et al. Soluble GC stimulators and activators: past, present and future[J]. Br J Pharmacol, 2024, 181(21):4130-4151.
|
| [17] |
Gawrys O, Kala P, Sadowski J, et al. Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?[J]. Eur J Pharmacol, 2025, 987:177175.
|
| [18] |
Cordwin DJ, Berei TJ, Pogue KT. The role of sGC stimulators and activators in heart failure with reduced ejection fraction[J]. J Cardiovasc Pharmacol Ther, 2021, 26(6):593-600.
|
| [19] |
Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis[J]. Ann Rheum Dis, 2012, 71(6):1019-1026.
|
| [20] |
Beyer C, Zenzmaier C, Palumbo-Zerr K, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling[J]. Ann Rheum Dis, 2015, 74(7):1408-1416.
|
| [21] |
Hewitson TD, Martic M, Darby IA, et al. Intracellular cyclic nucleotide analogues inhibit in vitro mitogenesis and activation of fibroblasts derived from obstructed rat kidneys[J]. Nephron Exp Nephrol, 2004, 96(2):e59-e66.
|
| [22] |
Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in heart failure: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(11):1324-1340.
|
| [23] |
Haghighat L, DeJong C, Teerlink JR. New and future heart failure drugs[J]. Nat Cardiovasc Res, 2024, 3(12):1389-1407.
|
| [24] |
Ahluwalia A, Foster P, Scotland RS, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment[J]. Proc Natl Acad Sci U S A, 2004, 101(5):1386-1391.
|
| [25] |
Kintos DP, Salagiannis K, Sgouros A, et al. Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)- ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities[J]. Bioorg Chem, 2024, 144:107170.
|
| [26] |
Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial[J]. JAMA, 2015, 314(21):2251-2262.
|
| [27] |
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20):1883-1893.
|
| [28] |
Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study[J]. JACC Heart Fail, 2020, 8(11):931-939.
|
| [29] |
Lam C, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial[J]. JAMA Cardiol, 2021, 6(6):706-712.
|
| [30] |
McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37):3627-3639.
|
| [31] |
Pieske B, Maggioni AP, Lam C, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study[J]. Eur Heart J, 2017, 38(15):1119-1127.
|
| [32] |
Armstrong PW, Lam C, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial[J]. JAMA, 2020, 324(15):1512-1521.
|
| [33] |
Udelson JE, Lewis GD, Shah SJ, et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial[J]. JAMA, 2020, 324(15):1522-1531.
|
| [34] |
Dachs TM, Duca F, Rettl R, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial[J]. Eur Heart J, 2022, 43(36):3402-3413.
|
| [35] |
Reddy Y, Butler J, Anstrom KJ, et al. Vericiguat global study in participants with chronic heart failure: design of the VICTOR trial[J]. Eur J Heart Fail, 2025, 27(2):209-218.
|
| [36] |
Saldarriaga CI, Zannad F, McMullan CJ, et al. Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: the VICTOR trial[J]. Eur J Heart Fail, 2025 ,27(8):1426-1435.
|